Physician

Vikas Malhotra, M.D.

According to 2025 Medicare claims, Vikas Malhotra, M.D. (NPI: 1821058496) practices hematology/oncology in the Tampa, FL market, with the plurality of this provider's patient population coming from Hernando, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 34609-5696.

Malhotra's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,280 traditional Medicare patients, billed 550,378 HCPCS/CPT codes, and received $6,872,235 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 4,338 prescription claims across 647 beneficiaries totaling $7,062,587 in drug costs, led by Revlimid (Lenalidomide). DME data shows 145 claims. Open Payments data shows 133 records totaling $8,373. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $3,138,719 to $7,062,587. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $19,323 and ending at $10,518.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,973	867,702	$9,325,681
2016	1,769	749,245	$8,057,248
2017	1,575	726,647	$7,696,088
2018	1,485	711,183	$6,755,259
2019	1,512	860,746	$8,286,965
2020	1,292	630,168	$7,682,932
2021	1,272	553,634	$7,410,100
2022	1,230	682,411	$7,243,755
2023	1,277	538,164	$6,457,788
2024	1,280	550,378	$6,872,235

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	586	3,805	$3,138,719
2016	582	3,551	$4,230,082
2017	567	3,188	$3,980,179
2018	619	3,227	$4,831,366
2019	623	3,728	$5,800,589
2020	602	3,805	$7,727,884
2021	616	3,683	$7,178,632
2022	624	3,971	$7,829,074
2023	613	3,791	$6,451,799
2024	647	4,338	$7,062,587

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	99	537	$90,881
2016	72	422	$81,733
2017	89	280	$50,855
2018	90	360	$40,038
2019	61	361	$35,584
2020	68	278	$20,883
2021	54	243	$17,859
2022	13	167	$8,955
2023	N/R	126	$14,978
2024	13	145	$6,789

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	606	1,944	$94
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	502	738	$63
96372	Injection of drug or substance under skin or into muscle	330	1,829	$10
36415	Insertion of needle into vein for collection of blood sample	1,096	4,266	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	1,089	4,594	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	65	1,820	$1,066,816
Ibrance	Palbociclib	50	1,400	$813,272
Imbruvica	Ibrutinib	52	1,518	$727,330
Jakafi	Ruxolitinib Phosphate	35	1,050	$588,173
Brukinsa	Zanubrutinib	39	1,170	$565,972

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	13	16	$2,869
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	21	$1,521
J8521	Capecitabine, oral, 500 mg	N	N/R	31	$1,045
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	15	$420
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	32	$401

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	133	$8,373	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Vikas Malhotra, M.D.?

Tedicare shows public-source Medicare data for Vikas Malhotra, M.D. (NPI 1821058496), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Vikas Malhotra, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Vikas Malhotra, M.D.?

Vikas Malhotra, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Vikas Malhotra, M.D. have Open Payments data?

Vikas Malhotra, M.D. has 133 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.